Application of PPARalpha agonist in treatment of psoriasis

The invention provides an application of a PPAR alpha agonist or a pharmaceutically acceptable salt thereof in preparation of a drug for treating psoriasis, and the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is used as an active ingredient and dissolved in a carrier solution...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SHI YULING, ZHUANG YU, MA RUI, MEI HAO, SHE XIAOMIN, CAI JIANGLUYI, GUO CHUNYUAN, CUI LIAN, CHEN QIANYU, YANG NAN, YAO LINGLING, WANG YUANYUAN
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention provides an application of a PPAR alpha agonist or a pharmaceutically acceptable salt thereof in preparation of a drug for treating psoriasis, and the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is used as an active ingredient and dissolved in a carrier solution to prepare the drug for treating psoriasis, wherein the PPARalpha agonist is WY14643, the carrier solution is a mixed solution of polyethylene glycol and ethanol, and the molecular weight of the polyethylene glycol is 200-600; in the medicine, the final concentration of the PPAR alpha agonist or the pharmaceutically acceptable salt thereof is 2-20mM, and the volume ratio of polyethylene glycol to ethanol is 9: 1-1: 9. The invention verifies the curative effect and the specific action mechanism of WY14643 on psoriasis for the first time: inhibiting the mRNA expression level of important chemotactic factors of psoriasis in keratinocytes; the WY14643 can effectively treat psoriasis, activate PPARalpha in skin, relieve